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ABSTRACT8
Background: Crohn’s disease (CD) patients suffer postprandial aversive symptoms which9
may lead to anorexia and malnutrition. Changes in the regulation of gut hormones and gut10
dysmotility are believed to play a role.11
Objective: This study aims to investigate small bowel motility and gut peptides responses to a12
standard test meal in CD by using Magnetic Resonance Imaging (MRI).13
Design: Fifteen CD patients with active disease (age 36±3 years, BMI 26±1 kg/m2) and 2014
healthy volunteers (HV) (age 31±3 years; body mass index, BMI 24±1 kg/m2) were studied.15
They underwent baseline and postprandial MRI scans, symptom questionnaires, and blood16
sampling following a 400g soup meal (204 kcal). Small bowel motility and other MRI17
parameters and glucagon-like peptide-1 (GLP-1), polypeptide YY (PYY), and cholecystokinin18
(CCK) peptides were measured. Data is presented as mean±standard deviation of the mean19
(SEM).20
Results: HV had significantly higher fasting motility index (106±13 a.u.) compared to CD21
participants (70±8 a.u., p≤0.05). Postprandial small bowel water content showed a significant 22
time by group interaction (p<0.05) with CD showing higher levels from t=210 min23
postprandially. Fasting levels of GLP-1 and PYY were significantly greater in CD compared24
to healthy volunteers (GLP-1, CD 50±8 µg/mL versus HV 13±3 µg/mL, p≤0.0001 and PYY, 25
CD 236±16 pg/mL versus HV 118±12 pg/mL, p≤0.0001). The meal challenge induced a 26
significant postprandial increase in aversive symptoms scores (fullness, distention, bloating,27
abdominal pain and sickness) in CD participants compared to healthy volunteers (p≤0.05). 28
Conclusions: The decrease in fasting small bowel motility noted in CD may be ascribed to the29
increased fasting gut peptides. A better understanding of the etiology of aversive symptoms in30
CD will facilitate identification of better therapeutic targets to improve nutritional status.31
5
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INTRODUCTION33
Malnutrition is common in patients with Crohn’s disease (CD). A recent systematic review34
reported a reduction in body mass index (BMI) in 37% of CD patients with a reduction in fat-35
free mass and fat mass in 28% and 31% respectively (1).36
Multiple reasons could account for the malnutrition but an abnormal eating behaviour is37
common in CD, with up to 37% of patients showing abnormal eating patterns (2), with an38
associated significant reduction in protein intake. Ingestion of food plays a predominant role in39
symptom generation in Inflammatory Bowel Disease (IBD) patients. In a large prospective40
multi-centre study, 77% of patients avoided some foods to prevent disease relapse, with 86%41
of patients avoiding foods when the disease is activity to prevent worsening symptoms (3).42
The aetiology for this is still unclear but postprandial dysmotility of the inflamed gut could be43
an aetiological factor. A delayed gastric empting or attenuated small bowel motility in the44
fasting or postprandial state could be an important aetiological factor in the patient symptom45
generation and eventual adoption of a diverse eating behaviour to improve symptom control.46
Recent technological advances in image analysis have allowed us to use magnetic resonance47
imaging (MRI) to measure CD activity through intestinal motility (4). A significant negative48
correlation is observed between terminal ileal motility and histological (4), biochemical (5)49
and radiological measures of disease activity (4). The exact aetiology of this50
pathophysiological finding is still unclear.51
Enteroendocrine cells (EC) are intraluminal nutrient sensors. They play a pivotal role in52
orchestrating physiological functions in the gastrointestinal tract. Exposure of the ileum to53
fatty acids decreases jejunal (6) and duodenal motility (7) through polypeptide YY (PYY)-54
mediated mechanisms. Glucagon-like peptide-1 (GLP-1) has been shown to decrease small55
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bowel motility (8, 9). Moreover, cholecystokinin (CCK) has been shown to delay gastric56
emptying by increasing pyloric motility (10, 11), with CCK modulation (12) affecting food57
intake underlying its anorectic role in eating behaviour. CD patients with active small bowel58
inflammation have significant up-regulation of EC cells with an increase in ileal expression of59
GLP-1 (13), PYY (2-fold) (14) and (CCK) (3-fold) (15) levels. This increase in plasma60
peptide levels is associated with the symptoms of nausea and anorexia, with both symptoms,61
and tissue and plasma EC-peptide expression decreasing to normality in remission (14). We62
hypothesise that an increase in CCK, GLP-1 or PYY-EC activity could potentially lead to63
symptoms of nausea through delayed gastric emptying and attenuated post-prandial small64
bowel motility. To our knowledge, this mechanistic link has never been described.65
We have shown that a soup test meal challenge is effective at inducing a change in multiple66
physiological quantified end-points and in monitoring markers of gastrointestinal motility in a67
single MRI study acceptable to participants (16, 17). Our developed technique for the68
assessment of small bowel motility showed excellent inter and intra observer agreement (17).69
We now aim to investigate fasting and postprandial changes in gut motility, intestinal70
physiology and related symptoms in a cohort of CD patients with active disease and healthy71
volunteers (HV) to investigate the aetiology of patient symptoms.72
SUBJECTS AND METHODS73
Study population74
This is a single-centre open-label clinical trial conducted between November 2015 and75
February 2017 at the National Institute of Health Research Nottingham Biomedical Research76
Centre (NIHR Nottingham BRC). CD patients (18-75 years) with active disease were77
recruited from the Inflammatory Bowel Disease clinic at Nottingham University Hospitals78
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Trust. Active disease was defined as ulceration seen at ileocolonoscopy, intestinal79
inflammation or deep ulceration seen on computer tomography or MR enterography, with the80
disease activity quantified via the Magnetic Resonance Index of Activity (MaRIA) score of81
>7 (18) or faecal calprotectin of >250µg/g (19, 20) or C-Reactive protein (CRP) >5mg/dl.82
These measures of disease activity were to be quantified within four weeks of recruitment.83
Stable doses of immunosuppressive and biological agents were permitted. No changes in84
medication were allowed at inclusion until data collection of the outcome measures has been85
completed. All participants had a good command of the English language and had the86
capacity to give informed written consent.87
Age-, body mass index- and gender-matched HV participants were recruited from an existing88
participant database in the NIHR Nottingham BRC and from the local healthy populations of89
Nottingham University Hospitals and the University of Nottingham. Potential participants90
with a history of inflammatory bowel disease, smokers (21), a history of bowel resections or91
any gastrointestinal surgery, history of pancreatic insufficiency, thyroid disease, diabetes,92
protein-pump inhibitor usage or any medication that affects gastric emptying or small bowel93
transit and any potential participants scoring very highly on the depression scale questionnaire94
were excluded. Standard MRI exclusion criteria were applied.95
This study was approved by the Research Ethics Committee (NRES approval 15/EM/0003) of96
the Health Research Authority. This study is registered on clinical trials.gov with identifier97
NCT03052465. All participants gave informed written consent.98
Outcome measures99
The primary outcome of this study was to compare fasting and postprandial small bowel100
motility between CD and HV participants as measured through MRI. Secondary outcomes101
9
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were gall bladder contraction, gastric volumes, small bowel water content, plasma GLP-1,102
PYY and CCK, symptoms scores and MRI disease activity scores as quantified by the MaRIA103
score (18).104
Experimental protocol105
This study was open label. Participants were asked to fast from 2000 h the previous evening106
and to avoid alcohol, caffeine, strenuous exercise and any medication that could affect gut107
function for 18 h before the experiment. On the day of the scan, participants attended the 1.5T108
Philips Achieva MRI scanner (Philips Healthcare, Best, the Netherlands) at the Sir Peter109
Mansfield Imaging Centre (SPMIC) at the University Park Campus, University of110
Nottingham at 0800.111
Participants underwent a baseline fasting scan (defined at t = -20 min time point), together112
with a fasting baseline blood sample. They were then asked to consume all their test meal113
within a maximum time of 20 min. The participants then underwent a first immediate114
postprandial scan (defined as t = 0 min).115
This was followed with data collection (MRI, questionnaire data and 10 ml blood samples)116
time points every 15 min for the first 60 min and then every 30 min up to 270 min. At each117
time point, participants filled a 100mm Visual analogue scale (VAS) symptoms questionnaire118
scoring their feeling of fullness, bloating, distension, abdominal pain/discomfort and nausea119
(14). At the end of the 270 min participants were given a volume (750mls-1250mls) of oral120
contrast agent (2.5% Mannitol,0.2 % locust bean gum) to drink (within 60 minutes) and a121
further MRI scan (within 30 minutes) was undertaken to quantify disease activity. See122
supplementary figure 1.123
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Test meal124
The test meal consisted of: cream of chicken soup (400g) (or mushroom for vegetarians)125
(Heinz, Wigan, UK) (14, 22), The nutrient content of this meal/100g was: energy (kcal) 51,126
protein 1.5 g (1.5%), carbohydrate 4.7 g (4.5%), fat 2.9 g (2.9%). For a complete list of127
contents please see https://www.heinz.co.uk/products/soup/ranges/classics/cream-of-chicken.128
Magnetic Resonance Imaging129
Participants were scanned using a range of sequences (22). At each time point scans were130
acquired to assess gastric volume (23), gall bladder volume (24), small bowel water content131
(25) and small bowel motility (26).132
Gastric emptying was assessed using a balanced gradient echo sequence to yield a good133
contrast between the stomach contents and other abdominal organs (23).134
The content of apparent freely mobile water in the small bowel was assessed as previously135
described (25). This sequence yields high-intensity signals from areas with freely mobile fluid136
and dark signals from poorly mobile or bound water and all other body tissues.137
Small bowel motility was assessed using a single slice cine-MRI acquisition set at six138
contiguous parallel coronal planes through the small bowel (22).139
Gall bladder volume was measured pre- and post-prandial, at every acquisition time point140
using the same images as for the gastric volumes as previously shown (24). These functional141
MRI measures were acquired prior to the use of any anti-spasmodic agents administered142
during serial image acquisition.143
Plasma collection and peptides assays analysis144
Fasting 10 ml blood sample was drawn and collected. After the test meal, data were acquired145
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every 15 min for the first 60 min and every 30 min thereafter to 270 min. Plasma peptides146
(total GLP-1, total PYY) were analysed through enzyme-linked immunosorbent assay147
(ELISA) techniques (Millipore, UK) as previously shown (14). The concentrations of serum148
CCK were measured by radioimmunoassay (RIA) (Euro Diagnostic Products, Sweden) as149
previously shown (27).150
MRI measures of disease activity151
Small bowel was scanned before and 10 minutes after 40mg of hyoscine butyl bromide was152
injected intravenously to reduce small bowel motility. Participants were scanned within 30153
minutes. Initially a true fast imaging with a steady sequence was acquired in the coronal154
plane. Axial T1 sequences were acquired before and 70 s after intravenous administration of155
0.2 ml/kg body weight of gadolinium chelate (gadodiamide 0.5 mmol/l) at a rate of 2 ml/s.156
Data analysis157
Motility assessment158
All dynamic data was processed with Dual Registration of Abdominal Motion (Motilent,159
London, UK). Registration results were further analysed using a customised graphical user160
interface written in MATLAB (MathWorks, Natick, MA, USA) (17).161
The technique used in this study quantified the motility of the bowel using the pixel signal162
changes through the time series, within a defined region of interest (ROI) placed over all163
visible small bowel loops (17) as previously described. This method utilizes changes in signal164
intensities that occur when the small bowel contents move between segments in regions165
showing bolus movement of contents as well as those showing more oscillatory motion, rather166
than looking for continuous motion throughout the time series. Motility measures are167
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presented as arbitrary units (a.u.) and are calculated as the mean across the total small bowel168
ROI.169
Small bowel water content (SBWC), Gall bladder and gastric volumes170
These parameters were quantified as previously validated (25), using in house software171
written in interactive data language (IDL) (Research Systems Inc. Boulder, Colorado, USA).172
Visual analogue scale (VAS)173
Symptoms regarding appetite, satiety and abdominal pain were scored at each time point174
using a previously validated questionnaire (14).175
MARIA score176
MRE variables were evaluated by a Nottingham University Hospitals clinical gastrointestinal177
(GI) MRI radiologist with > 10 years’ experience (Dr. Khalid Latief) in each segment178
including: bowel wall thickening, enhancement of the bowel wall after administration of179
intravenous contrast with gadolinium (relative contrast enhancement), presence of ulcers,180
mural oedema, regional enlarged lymph nodes (>10 mm), peri-enteric vascularization (comb181
sign), peri-enteric fluid, fat stranding, and fibro-fatty proliferation. The MaRIA score in each182
segment was calculated according to a formula, as previously defined (18).183
Sample size and Statistical analyses184
Previous literature showed 2-fold higher plasma PYY in CD (area under the curve, AUC 22990185
± 5585) vs HV (10700 ± 1886) and a higher plasma GLP-1 in CD (AUC 1027 ± 220) vs HV186
(1347 ± 350) (28). Assuming α of 0.05, power of 80%, a maximum sample of 15 participants 187
in each group was needed to show a difference. Similar comparisons for CCK showed188
significant differences between CD and HV in 10 participants/group with a strong correlation189
(r=0.6) between mean CCK plasma concentration and gastric emptying half-life (15). Assuming190
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α of 0.05, power of 80% a total sample size of 19 participants was needed to show a difference. 191
To allow for missing data (~10%), we aimed to recruit a maximum of 20 participants in each192
of the CD and HV cohorts.193
The primary analysis was an across-group analysis with further sub-analyses undertaken if the194
primary comparison is significant. Normality of the data was assessed using Shapiro–Wilk’s195
test. Parametric data was presented as mean ± standard error of the mean (SEM) or median ±196
interquartile range if non-parametric. All statistical analyses were performed using GraphPad197
Prism 7.01 (La Jolla, USA). A p-value less than 0.05 was considered statistically significant.198
Analyses of variance (ANOVA) was used to assess the significance of differences between199
and within each group with different time points. When the analysis of variance was200
significant, post hoc test assessments of the individual time points were performed using the201
Dunnett’s (for parametric data) or Dunn’s test (for nonparametric data) for within group202
comparison and Sidak's test was used for between groups to account for multiple203
comparisons. The Pearson correlation coefficient was used to measure the strength of204
correlation between MaRIA scores and the different variables (measured as AUC).205
RESULTS206
Participants207
Nineteen CD participants with active disease (age 36±3 years, BMI 26±1 kg/m2) as well as 20208
HV participants (age 31±3 years, BMI 24±1 kg/m2) were recruited. One CD participant was209
lost to follow-up and the data from two CD participants were excluded from the final210
analyses: one because of a low MaRIA score of 3.39 and another because of an unanalysable211
MRI data set. One other participant was excluded because of a high score on the hospital212
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anxiety and depression questionnaire. See supplementary figure 2, table 1 and supplementary213
table 1. CD participants had a mean disease duration of 12.3±1.7 years, mean HBI of 6±1,214
mean CRP of 18.2±3.4mg/dl and mean fecal calprotectin of 787.2±146.8µg/g. All patients215
had ileal involvement. Four patients were being prescribed anti-tumor necrosis factor therapy,216
one patient vedolizumab, three patients immunomodulators, with the rest on no medication at217
the time of recruitment. Eight patients were surgically naïve.218
All HV participants and CD participants completed the study and tolerated the experimental219
procedures well without any adverse event.220
Small bowel motility221
The HV participants started with a significantly higher (106±13 a.u., p<0.05) fasting motility222
index compared to CD participants (70±8 a.u.) (Figure 1). No significant difference in the223
postprandial time by group interaction was observed in small bowel motility between the CD224
and HV groups.225
Gallbladder volumes226
Two CD patients had a cholecystectomy prior to recruitment. No difference in the fasting gall227
bladder volumes were observed between the two groups. No significant difference in the228
postprandial time by group interaction was observed in gall bladder volumes between the CD229
and HV groups. The difference in gallbladder volumes between HV and CD participants from230
fasting to 150 min are shown in Figure 2.231
Gastric volumes232
The baseline gastric volumes showed a small amount of fasting gastric secretions (Figure 3,233
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HV: 29±5 mL, CD: 25±4 mL) with no differences observed between the groups. No234
significant difference in the postprandial time by group interaction was observed in gastric235
volumes between the CD and HV groups. Gastric volume increased upon feeding (HV:236
388±18 mL, CD: 324±26 mL). The average time to empty half of the stomach contents (T1/2)237
in HV and CD participants was 43±4 min, 63±7.5 min respectively, with no significant238
difference observed between the groups.239
Small bowel water content240
The data in Figure 4 shows a small amount of fasting small bowel water content in both241
groups (HV: 44±6 mL, CD: 36±9 mL). No difference in the fasting small bowel water content242
was visualised between groups. A significant increase (p<0.05) was seen in CD participants243
compared to HV (measured as area under the curve (AUC) CD: 19778±2119 mL/min, HV:244
14197±1249 mL/min). A significant difference in the time by group interaction was observed245
in small bowel water content between the CD and HV groups (p=0.0352). An increase in246
postprandial water volume in CD when compared to healthy volunteers was observed at247
t=210 min (p=0.0388), t=240 min (p=0.0168) and 270 min (p=0.0048).248
Total GLP-1249
Figure 5 show higher (p<0.0001) fasting GLP-1 levels in CD participants compared to HV250
(CD: 50±8 µg/mL, HV: 13±3 µg/mL). The test meal did not induce a significant postprandial251
response in either group. No significant difference in the time by group interaction was252
observed between HV and CD groups. Significantly higher (p<0.0001) postprandial GLP-1253
levels were reported in CD participants compared to HV (AUC CD: 12293±1586 µg/mL, HV:254
3317±762 µg/mL).255
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Total PYY256
The CD participants showed higher (236±16 pg/mL, p<0.0001) fasting PYY plasma levels257
when compared to HV (118±12 pg/mL) (Figure 6). The test meal did not induce a significant258
postprandial response in either group. No significant difference in the time by group259
interaction was observed between HV and CD groups. CD participants exhibited a260
significantly higher postprandial PYY response compared to the HV (AUC CD: 62782±4313261
pg /mL, HV: 34744±3169 pg/mL, p<0.0001).262
CCK263
No significant difference was seen in fasting and postprandial levels of CCK between the two264
groups (Figure 7). No significant difference in the time by group interaction was observed in265
postprandial CCK between the CD and HV groups. In CD group, a significant difference266
(p<0.0001) was seen across the different time points with a significant increase (p<0.05) from267
time 0 to 90 min compared to fasting plasma levels. Within HV group, plasma CCK levels268
showed a significant increase (p<0.05) immediately after feeding to 60 min in comparison to269
fasting concentrations.270
Symptom VAS data271
Fasting and postprandial VAS scores recorded from CD participants and HV are shown in272
Figure 8. CD participants showed a significantly higher (p<0.01) fasting fullness and273
abdominal pain scores compared to HV (CD: 21±6 mm, 18±5 mm HV: 5±3 mm, 0.5±0.3274
mm). CD participants also showed a significantly higher (p<0.05) fasting distention scores275
compared to HV (CD: 14±5 mm HV: 2±1 mm).276
No significant difference in the time by group interaction was observed in VAS between the277
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CD and HV groups. The meal induced a significantly (p<0.05) higher postprandial fullness278
scores in CD participants compared to HV (AUC CD: 6795±1440 mm/min HV: 2907±703279
mm/min). A significantly higher postprandial (p<0.0001) VAS scores of bloating, distention280
and abdominal pain were noted in CD participants compared to HV (AUC CD: 5558±1293281
mm/min, 5071±1253 mm/min, 3187±873 mm/min HV: 565±257 mm/min, 303±191 mm/min,282
7±5 mm/min). The CD participants showed a significantly (p<0.01) higher sickness scores283
compared to HV healthy volunteers (AUC, CD: 2024±927 mm/min HV: 75±75 mm/min).284
MaRIA scores285
The mean value of the MaRIA score was 20.3±1.9 (see the supplementary table for individual286
scores). There was moderate non-significant correlation between fasting small bowel motility287
and disease activity as measured through MaRIA scores (r=0.52 (95% confidence interval -288
0.050, 0.8303, p=0.07). There was no significant correlation between MaRIA scores and289
postprandial small bowel motility, small water content and GLP-1, PYY or CCK levels.290
DISCUSSION291
The primary aim of this study was to understand the altered intestinal physiology and aversive292
patient symptoms observed in active CD in the fasted and the postprandial state. Any293
alterations might help better understand symptom generation that may be leading to altered294
eating behaviour and malnutrition.295
Participants with CD had a lower fasting small bowel intestinal motility, with otherwise no296
difference observed in the postprandial phase when compared to HV. We have shown297
significantly higher fasting and postprandial levels for both GLP-1 and PYY with associated298
aversive symptoms being reported to a significantly greater extent in CD than in HV.299
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Although small bowel hypomotility, elevated plasma GI peptide levels and aversive patient300
symptoms could be interlinked in the fasting state; our data suggests that this hypothesis may301
not hold true in the postprandial phase. Possibly, symptom generation in the postprandial302
phase could be related to GI-peptide mediated alterations in the gut-brain axis rather than303
altered intestinal physiology. A decrease in MR motility in CD, in the prepared bowel, was304
previously described, with motility correlated to histological and biochemical measures of305
disease activity and patient symptoms (29). Global small bowel hypomotility involving306
normal-looking bowel has been described in CD, with motility variance negatively correlating307
to key patient symptoms like diarrhoea, pain and clinical symptom scores (29, 30).308
The fasting and postprandial plasma levels of GLP-1 were significantly higher in CD. This309
was confirmed in previous CD studies (31). Similarly, plasma fasting and postprandial PYY310
levels were significantly elevated in CD group as we previously described (14, 31). The311
higher fasting GLP-1 and PYY observed in CD could be the cause of the fasting small bowel312
hypomotility observed in CD. We observed no difference in the fasting and postprandial313
plasma CCK levels, although the observed postprandial CCK response was only significant in314
the CD rather than the healthy group despite the absolute levels not being significant in315
between groups. The CD location in this recruited cohort was predominantly ileal or316
ileocolonic rather than proximal in the duodenum where the CCK-secreting I cells are located.317
Although earlier data in IBD murine models suggested that EC upregulation occurs318
irrespective of the anatomical location of intestinal inflammation (32), this observation was319
later refuted in CD (13). This might explain the lack of difference in CCK concentration320
between both groups.321
No significant difference was seen in the fasting and postprandial gall bladder volumes in CD322
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compared to healthy volunteers. The lack of difference in CCK levels between the two groups323
explains the lack of difference in the gall bladder volumes as CCK is integral for the gall324
bladder contraction in response to a fat stimulus. Additionally, previous data showed a similar325
non-significant fasting gall bladder volumes in both healthy volunteers and patients with326
small bowel CD (33, 34).327
Similarly to postprandial small bowel motility, a delay in gastric emptying was expected in328
the CD cohort with no difference in gastric emptying observed between CD and HV in this329
study. Both PYY and GLP-1 may delay gastric emptying (35). In a previous study, delayed330
gastric emptying was observed in an inflammatory bowel disease cohort with similar plasma331
CCK and elevated plasma GLP-1 to healthy participants (31). In that study, gastric emptying332
was measured through a breath test so the findings are not comparable to our study.333
Postprandial small bowel water content typically showed two peaks. The first peak is the334
gastric phase and represents emptying of the gastric contents in the proximal small bowel. The335
second peak is called the intestinal phase (36) which represents the increase in small bowel336
water content due pancreatico-biliary and enterocyte secretion. A bimodal postprandial peak337
was also seen in the small bowel water content in CD group, with a significant difference in338
time by group interaction in postprandial small bowel water content between CD and HV. The339
noted increase could be due to the significant postprandial CCK response in the CD group340
which leads to an increase in bile acid production and pancreatic secretion. Additionally, the341
meal may have acted as an osmotic stimulus causing the increase in the small bowel water342
content seen in the intestinal phase in CD cohort (37). Moreover, the observed increase in343
small bowel water content in CD group might have induced an increase in small bowel344
motility by stimulating smooth muscle contraction due to the increase in small bowel345
20
20
distention thus nullifying any postprandial differences between groups. Additionally, the346
increase in small bowel distention might have made small bowel motility more easily347
quantifiable in this unprepared MRI visit hence decreasing any possible difference to healthy348
participants. None of the CD participants had predominant stricture which may have caused a349
delay in intestinal transit and might explain the increase in small bowel water content. Finally,350
the increase in measureable small bowel water content in CD might merely represent a delay351
in the distal small bowel emptying its contents in the ascending colon.352
The CD group demonstrated significantly higher fasting and postprandial symptom VAS353
scores, with more predominant symptoms of fullness, distention and abdominal pain scores354
compared to HV. The additional small bowel distention from the increase in water content in355
CD might explain the significant difference in the measured symptoms. However, the actual356
difference in small bowel water content is small and accounts to only 40 mL which might not357
been enough to account for such a drastic difference in symptoms. Another possible mechanism358
for these exaggerated symptoms might be from the upregulated gut-brain axis which we have359
not investigated in this study.360
There were possible limitations to this work. The test meal used was small in volume and361
nutrients and did not induce a significant change in postprandial GLP-1, PYY and CCK.362
However, as we had previously shown (14), it was well tolerated by all the patients and acted363
as a good stimulus to gastrointestinal physiological responses. Another limitation is the364
relatively small participant population, but such detailed phenotyping made recruiting a larger365
cohort for this exploratory study unfeasible. We as well assayed total PYY and GLP-1 rather366
than the active peptides. In vivo, active GLP-1 is rapidly degraded to GLP-1 (9-36). Similarly,367
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PYY (1-36) is metabolised to the active PYY (3-36). Both of these activities are undertaken368
through DPP-4 (38, 39).We have previously shown that DPP-4 expression is decreased in CD369
(40). In this present study, we used a protease inhibitor to further minimise DPP4 activity and370
peptide degradation. In previous work we also have shown no significant difference between371
active and total GLP-1 in small bowel CD and HV (28). Similarly, total PYY, has been shown372
to have a temporal pattern similar to that of PYY (3–36) after meals (41). For these reasons, we373
assayed total rather than the active peptides.374
In this work we successfully quantified fasting and postprandial small bowel motility and375
possibly ascribed a putative role for EC peptides in the aetiology of disordered intestinal376
motility and anorectic symptoms in CD. A better understanding of the role EC peptides in the377
altered eating behaviour and malnutrition has pharmacological relevance. EC peptide378
modulators (Exendin 9-39 (42) and dexloxiglumide (43)) are now available. Further work is379
now needed to deconstruct the gut-brain axis and possibly open a new therapeutic pathway in380
CD therapy, thus improving nutritional status, disease outcomes and quality of life.381
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Tables 1: Patient demographics
HV participants CD participants
Number 20 15
Age 31±3 years 36±3 years
Gender 10F:10M 8F:8M
BMI 24±1 kg/m2 26±1 kg/m2
Smoking Status Non-smokers Non-smokers
Mean CRP (SEM) N/A 18.2±3.4mg/dl
Mean Faecal
Calprotectin (SEM)
N/A 787.2±146.8µg/g
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Figure legends:
Figure 1: Time courses of the small bowel motility in Crohn’s disease (CD) and in healthy
volunteers. A. Significantly lower fasting small bowel motility in CD when compared to healthy
volunteers. B. Time courses of the small bowel motility for CD and healthy volunteer. No
significant difference in the time by group interaction was observed between CD and healthy
volunteer groups. Data presented as mean ± SEM (healthy volunteer: n=20, CD: n=15).
ANOVA was used to assess the significance of differences between and within each group for
different time points.
Figure 2: Time courses of the gallbladder volumes in Crohn’s disease (CD) and in healthy
volunteer groups. A. No significant difference in the fasting gall bladder volumes between CD
and healthy volunteer groups. B. Time courses of the gall bladder volumes in CD and healthy
volunteer groups. No significant difference in the time by group interaction was observed
between CD and healthy volunteer groups. Data presented as mean ± SEM (healthy volunteer:
n=20, CD: n=13). ANOVA was used to assess the significance of differences between and
within each group for different time points.
Figure 3: Time courses of the stomach content volumes in Crohn’s disease (CD) and in healthy
volunteers. A. No significant difference in the fasting stomach volumes between CD and
healthy volunteers. B. Time courses of the stomach volumes for CD and healthy volunteers. No
significant difference in the time by group interaction was observed between CD and healthy
volunteer groups. Data presented as mean ± SEM (healthy volunteers: n=20, CD: n=15).
ANOVA was used to assess the significance of differences between and within each group for
different time points.
Figure 4: Time courses of the small bowel water content in Crohn’s disease (CD) and in healthy
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volunteers. A. No significant difference in the fasting small bowel water content for CD and
healthy volunteers. B. Time courses of the small bowel water content for CD and healthy
volunteers showing a significant difference in time by group interaction (p=0.0352) with an
increase in postprandial water volume in CD when compared to healthy volunteers at t=210
min (p=0.0388), t=240 min (p=0.0168) and 270 min (p=0.0048). Data presented as mean ±
SEM (healthy volunteers: n=20, CD: n=15). ANOVA was used to assess the significance of
differences between and within each group with different time points. Sidak's test was used for
the assessments of the individual time points between groups.
Figure 5: Time courses of the GLP-1 concentrations in Crohn’s disease (CD) and in healthy
volunteers. A. Significantly higher fasting GLP-1 concentrations for CD when compared to
healthy volunteers. B. Time courses of the GLP-1 concentrations for CD and healthy
volunteers. No significant difference in the time by group interaction was observed between
CD and healthy volunteer groups. CD participants exhibited a significantly higher
postprandial GLP-1 response compared to healthy volunteers (AUC CD: 12293±1586 µg/mL,
healthy volunteers: 3317±762 µg/mL, p<0.0001). Data presented as mean ± SEM (healthy
volunteers: n=20, CD n=15). ANOVA was used to assess the significance of differences
between and within each group for different time points.
Figure 6: Time courses of the PYY concentrations in Crohn’s disease (CD) and in healthy
volunteers. A. Significantly higher fasting PYY concentrations in CD when compared to
healthy volunteers. B. Time courses of the PYY concentrations for CD and healthy
volunteers. No significant difference in the time by group interaction was observed between
CD and healthy volunteer groups. CD participants exhibited a significantly higher
postprandial PYY response compared to healthy volunteers (AUC CD: 62782±4313 pg /mL,
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healthy volunteers: 34744±3169 pg/mL, p<0.0001). Data presented as mean ± SEM (healthy
volunteers: n=20, CD n=15). ANOVA was used to assess the significance of differences
between and within each group for different time points.
Figure 7: Time courses of the CCK concentrations in Crohn’s disease (CD) and in healthy
volunteers. A. No significant difference in fasting CCK concentrations between CD and healthy
volunteers. B. Time courses of the CCK concentrations for CD and healthy volunteers. No
significant time by group interaction observed. Data are mean ± SEM (healthy volunteers:
n=20, CD n=15). ANOVA was used to assess the significance of differences between and
within each group for different time points.
Figure 8: Time courses of the fasting and postprandial VAS scores in in Crohn’s disease (CD)
and in healthy volunteers. CD participants showed a significantly higher fasting fullness
(p<0.01), abdominal pain (p<0.01) and distention scores (p<0.05) compared to healthy
volunteers. Data presented as mean ± SEM (HV: n=20, CD n=15). ANOVA was used to assess
the significance of differences between and within each group for different time points.
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Supplementary table 1
Table summarising the demographics and key clinical variables of the CD subjects; Con
Meds=concomitant medication at the time of recruitment, MaRIA=Magnetic Resonance Index
of Activity, HBI-Harvey-Bradshaw Index, CRP=C-Reactive Protein, fC=Faecal Calprotectin,
u/a=unavailable.
Age
years
Sex
Disease
Duration
years
Montreal
Classificat
ion
Con Meds Surgical
History MaRI
A
HBI
CRP
mg/dl
fC
µg/g
1 24 F 12 A1L1B2 Adalimumab Right
hemicolectomy
16.10 2 41 933
2 29 F 4 A2L1B2 Adalimumab No 11.37 2 7 177
3 39 F 14 A2L1B2 Adalimumab No 16.72 13 <5 1435
4 57 M 8 A3L3B1 Methotrexate No 27.48 1 15 393
5 20 F 3 A2L1B1 Nil No 7.00 6 <5 275
6 52 F 25 A2L1B1p Nil Right
hemicolectomy
27.07 7 <5 107
7 30 M 8 A2L1B3p Nil Right
hemicolectomy
24.54 9 32 u/a
8 33 M 3 A2L1B1 Nil Right
hemicolecomy
13.65 2 <5 577
9 46 M 15 A2L1B3 Nil No 17.50 2 10 u/a
10 33 M 4 A2L1B2 Adalimumab No 33.75 2 <5 1023
11 51 F 37 A1L1B2 Methotrexate
Vedolizumab
3 small bowel
resections
17.00 5 9 535
12 30 F 15 A1L3B1 nil Subtotal
colectomy
17.06 6 <5 604
13 53 M 27 A2L1B2 Methotrexate Right
hemicolectomy,
small bowel
resection,
ileocolic
resection
23.68 2 <5 1800
14 23 F 3 A2L1B1 Azathioprine No 24.49 6 13 1587
15 19 M 6 A1L1B1 Nil No 27.48 18 <5 u/a
